Embecta closed its acquisition of Owen Mumford Holdings on Friday, shifting its focus from diabetes products to broader medical supplies.
Embecta, which announced the deal in March, agreed to pay 100 million pounds upfront, plus up to 50 million pounds in performance-based payments based on sales of Owen Mumford’s Aidaptus auto-injector platform in the three years after closing. In total, Embecta could pay up to 150 million pounds, the equivalent of roughly $201 million.
U.K.-based Owen Mumford makes medical products including auto-injectors, lancets and syringes. The company’s Aidaptus device can adapt to prefilled syringes of different sizes and fill levels.
Embecta, which has focused on insulin injection, makes supplies including pen needles and syringes.The company expects the acquisition to help it expand into other markets, including autoimmune diseases and anaphylaxis. Embecta also expects to benefit from Owen Mumford’s device design, molding and assembly capabilities.
When the deal was announced, Embecta said it expected Owen Mumford to contribute to revenue growth in its 2027 fiscal year.
